IFRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
InflaRx N.V.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 20, 2026
$1.45+0.13 (+9.85%)
Close on Oct 19, 2026
Share price
+$0.27 (+22.88%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
InflaRx N.V. saw revenue fall 82.3% to €29.33K over fiscal 2025.
Revenue
€29.33K
-82.3% vs. a year earlier
EPS, diluted
-0.68 EUR
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- €29.33K
- EPS, diluted
- -0.68 EUR
Valuation needs the share price. It fills in once daily prices are connected and converted from EUR.
Twelve years at a glance
Fiscal years 2014 to 2025, EUR
Revenue
€29.33K-82.3% YoY
Gross profit
-€7.24M
Operating income
–
EPS, diluted
-0.68 EUR
Reported period